Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Adherence in multiple sclerosis (ADAMS): classification, relevance, and research needs. A meeting report.

Heesen C, Bruce J, Feys P, Sastre-Garriga J, Solari A, Eliasson L, Matthews V, Hausmann B, Ross AP, Asano M, Imonen-Charalambous K, Köpke S, Clyne W, Bissell P.

Mult Scler. 2014 Nov;20(13):1795-8. doi: 10.1177/1352458514531348. Epub 2014 Apr 22.

PMID:
24756569
2.

Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study).

Jongen PJ, Hengstman G, Hupperts R, Schrijver H, Gilhuis J, Vliegen JH, Hoogervorst E, van Huizen M, van Munster E, Samijn J, de Schryver E, Siepman T, Tonk M, Zandbergen E, ten Holter J, van der Kruijk R, Borm G.

BMC Neurol. 2011 Mar 30;11:40. doi: 10.1186/1471-2377-11-40.

3.

Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term.

Costello K, Kennedy P, Scanzillo J.

Medscape J Med. 2008;10(9):225. Epub 2008 Sep 30. Review.

4.

Factors that influence adherence and strategies to maintain adherence to injected therapies for patients with multiple sclerosis.

Saunders C, Caon C, Smrtka J, Shoemaker J.

J Neurosci Nurs. 2010 Oct;42(5 Suppl):S10-8.

PMID:
21049829
5.

Fostering adherence to injectable disease-modifying therapies in multiple sclerosis.

Lugaresi A, Rottoli MR, Patti F.

Expert Rev Neurother. 2014 Sep;14(9):1029-42. doi: 10.1586/14737175.2014.945523. Epub 2014 Aug 11. Review.

PMID:
25109614
6.

Medication adherence with disease modifying treatments for multiple sclerosis among US employees.

Kleinman NL, Beren IA, Rajagopalan K, Brook RA.

J Med Econ. 2010;13(4):633-40. doi: 10.3111/13696998.2010.527588. Epub 2010 Oct 19.

PMID:
20958113
7.

Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?

Lugaresi A.

Expert Opin Drug Deliv. 2009 Sep;6(9):995-1002. doi: 10.1517/17425240903134769. Review.

PMID:
19637982
8.

Adherence to behavioural interventions in multiple sclerosis: Follow-up meeting report (AD@MS-2).

Heesen C, Bruce J, Gearing R, Moss-Morris R, Weinmann J, Hamalainen P, Motl R, Dalgas U, Kos D, Visioli F, Feys P, Solari A, Finlayson M, Eliasson L, Matthews V, Bogossian A, Liethmann K, Köpke S, Bissell P.

Mult Scler J Exp Transl Clin. 2015 May 12;1:2055217315585333. doi: 10.1177/2055217315585333. eCollection 2015 Jan-Dec.

9.

Enhancing adherence through education.

Smrtka J, Caon C, Saunders C, Becker BL, Baxter N.

J Neurosci Nurs. 2010 Oct;42(5 Suppl):S19-29.

PMID:
21049830
10.

Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study.

Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersley MA.

Clin Drug Investig. 2010;30(2):89-100. doi: 10.2165/11533330-000000000-00000.

PMID:
20067327
11.

Use of an online community to develop patient-reported outcome instruments: the Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ).

Wicks P, Massagli M, Kulkarni A, Dastani H.

J Med Internet Res. 2011 Jan 24;13(1):e12. doi: 10.2196/jmir.1687.

12.

Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.

Bergvall N, Petrilla AA, Karkare SU, Lahoz R, Agashivala N, Pradhan A, Capkun G, Makin C, McGuiness CB, Korn JR.

J Med Econ. 2014 Oct;17(10):696-707. doi: 10.3111/13696998.2014.940422. Epub 2014 Jul 23.

PMID:
25019581
13.

Intentional non-adherence to medications by older adults.

Mukhtar O, Weinman J, Jackson SH.

Drugs Aging. 2014 Mar;31(3):149-57. doi: 10.1007/s40266-014-0153-9. Review.

PMID:
24566876
14.

Adherence to disease-modifying therapies and attitudes regarding disease in patients with multiple sclerosis.

Ožura A, Kovač L, Sega S.

Clin Neurol Neurosurg. 2013 Dec;115 Suppl 1:S6-11. doi: 10.1016/j.clineuro.2013.09.013.

PMID:
24321157
15.

Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis.

Tan H, Cai Q, Agarwal S, Stephenson JJ, Kamat S.

Adv Ther. 2011 Jan;28(1):51-61. doi: 10.1007/s12325-010-0093-7. Epub 2010 Dec 6.

PMID:
21153000
16.

Managed approaches to multiple sclerosis in special populations.

Sperandeo K, Nogrady L, Moreo K, Prostko CR.

J Manag Care Pharm. 2011 Nov-Dec;17(9 Suppl C):S1-19; quiz S20-1. Review.

PMID:
22107156
17.

Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs.

Reynolds MW, Stephen R, Seaman C, Rajagopalan K.

J Med Econ. 2010 Mar;13(1):90-8. doi: 10.3111/13696990903579501.

PMID:
20078189
18.

Adherence to multiple, prescribed medications in diabetic kidney disease: A qualitative study of consumers' and health professionals' perspectives.

Williams AF, Manias E, Walker R.

Int J Nurs Stud. 2008 Dec;45(12):1742-56. doi: 10.1016/j.ijnurstu.2008.07.002. Epub 2008 Aug 13.

PMID:
18701103
19.

Implications of real-world adherence on cost-effectiveness analysis in multiple sclerosis.

Brandes DW, Raimundo K, Agashivala N, Kim E.

J Med Econ. 2013;16(4):547-51. doi: 10.3111/13696998.2013.774281. Epub 2013 Feb 21.

PMID:
23391123
20.

Adherence of adolescents to multiple sclerosis disease-modifying therapy.

Thannhauser JE, Mah JK, Metz LM.

Pediatr Neurol. 2009 Aug;41(2):119-23. doi: 10.1016/j.pediatrneurol.2009.03.004.

PMID:
19589460

Supplemental Content

Support Center